These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 32434151

  • 21. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P.
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [Abstract] [Full Text] [Related]

  • 22. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R, Strand DW, Forbes CM, Case T, Cates JMM, Liu Q, Ramirez-Solano M, Milne GL, Sanchez S, Wang ZY, Bjorling DE, Miller NL, Matusik RJ.
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [Abstract] [Full Text] [Related]

  • 23. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.
    Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM.
    J Urol; 2016 Nov; 196(5):1493-1498. PubMed ID: 27378134
    [Abstract] [Full Text] [Related]

  • 24. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L, Karashchuk E, Prokofyeva A, Loparev S.
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [Abstract] [Full Text] [Related]

  • 25. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, Lyon JA, Singh SK, Mandal AK.
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [Abstract] [Full Text] [Related]

  • 26. Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial.
    Kramer JJ, Gu L, Moreira D, Andriole G, Freedland SJ, Csizmadi I.
    Prostate; 2023 Jul; 83(10):990-997. PubMed ID: 37070723
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effects of Testosterone Level on Lower Urinary Tract Symptoms.
    Crawford ED, Poage W, Nyhuis A, Price DA, Dowsett SA, Muram D.
    Am J Mens Health; 2016 Sep; 10(5):440-2. PubMed ID: 26077271
    [Abstract] [Full Text] [Related]

  • 29. Making shared decisions with older men selecting treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH): a pilot randomized trial.
    Ngu H, Neo SH, Koh EYL, Ho H, Tan NC.
    J Patient Rep Outcomes; 2022 Oct 15; 6(1):112. PubMed ID: 36242683
    [Abstract] [Full Text] [Related]

  • 30. Depressive symptoms in individuals diagnosed with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in middle-aged and older Chinese individuals: Results from the China Health and Retirement Longitudinal Study.
    Zhang W, Cao G, Sun Y, Wu F, Wang Q, Xu T, Hu H, Xu K.
    J Affect Disord; 2022 Jan 01; 296():660-666. PubMed ID: 34565588
    [Abstract] [Full Text] [Related]

  • 31. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial.
    Rastrelli G, Cipriani S, Lotti F, Cellai I, Comeglio P, Filippi S, Boddi V, Della Camera PA, Santi R, Boni L, Nesi G, Serni S, Gacci M, Maggi M, Vignozzi L.
    J Endocrinol Invest; 2022 Jul 01; 45(7):1413-1425. PubMed ID: 35298833
    [Abstract] [Full Text] [Related]

  • 32. Association of lower urinary tract symptom/benign prostatic hyperplasia measures with international index of erectile function 5 in middle-aged policemen of Korea and the role of metabolic syndrome and testosterone in their relationship.
    Lee JH, Kwon H, Park YW.
    Urology; 2013 Nov 01; 82(5):1008-12. PubMed ID: 24041675
    [Abstract] [Full Text] [Related]

  • 33. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi K, Mikami K, Ota S, Okano T, Hamano S, Ohki T, Furuya Y, Ichikawa T.
    Int J Urol; 2006 Sep 01; 13(9):1202-6. PubMed ID: 16984553
    [Abstract] [Full Text] [Related]

  • 34. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC.
    BJU Int; 2016 Jul 01; 118(1):153-60. PubMed ID: 26765325
    [Abstract] [Full Text] [Related]

  • 35. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, Castro R.
    BJU Int; 2014 Apr 01; 113(4):623-35. PubMed ID: 24127818
    [Abstract] [Full Text] [Related]

  • 36. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Jung JH, McCutcheon KA, Borofsky M, Young S, Golzarian J, Kim MH, Narayan VM, Dahm P.
    Cochrane Database Syst Rev; 2022 Mar 29; 3(3):CD012867. PubMed ID: 35349161
    [Abstract] [Full Text] [Related]

  • 37. [Ultrasound indicators of the prostate, urinary bladder and uroflowmetry parameters in the diagnosis of infravesical obstruction in men with benign prostatic hyperplasia].
    Krivoborodov GG, Efremov NS, Bolotov AD.
    Urologiia; 2017 Oct 29; (5):9-14. PubMed ID: 29135135
    [Abstract] [Full Text] [Related]

  • 38. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume.
    Xia BW, Zhao SC, Chen ZP, Chen C, Liu TS, Yang F, Yan Y.
    Prostate; 2020 May 29; 80(6):481-490. PubMed ID: 32104919
    [Abstract] [Full Text] [Related]

  • 39. Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia.
    Tan MO, Karabiyik I, Uygur MC, Diker Y, Erol D.
    Int Urol Nephrol; 2003 May 29; 35(3):357-63. PubMed ID: 15160539
    [Abstract] [Full Text] [Related]

  • 40. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF, Jiang YH, Kuo HC.
    Int J Clin Pract; 2013 Dec 29; 67(12):1327-33. PubMed ID: 24246211
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.